Adrenoleukodystrophy epidemiology and demographics: Difference between revisions
Ibtisamshrf (talk | contribs) |
Ibtisamshrf (talk | contribs) |
||
| Line 17: | Line 17: | ||
*The lifetime '''prevalence of adrenal insufficiency''' in ALD is ~80%. <ref name="HuffnagelLaheji2019">{{cite journal|last1=Huffnagel|first1=Irene C|last2=Laheji|first2=Fiza K|last3=Aziz-Bose|first3=Razina|last4=Tritos|first4=Nicholas A|last5=Marino|first5=Rose|last6=Linthorst|first6=Gabor E|last7=Kemp|first7=Stephan|last8=Engelen|first8=Marc|last9=Eichler|first9=Florian|title=The Natural History of Adrenal Insufficiency in X-Linked Adrenoleukodystrophy: An International Collaboration|journal=The Journal of Clinical Endocrinology & Metabolism|volume=104|issue=1|year=2019|pages=118–126|issn=0021-972X|doi=10.1210/jc.2018-01307}}</ref> | *The lifetime '''prevalence of adrenal insufficiency''' in ALD is ~80%. <ref name="HuffnagelLaheji2019">{{cite journal|last1=Huffnagel|first1=Irene C|last2=Laheji|first2=Fiza K|last3=Aziz-Bose|first3=Razina|last4=Tritos|first4=Nicholas A|last5=Marino|first5=Rose|last6=Linthorst|first6=Gabor E|last7=Kemp|first7=Stephan|last8=Engelen|first8=Marc|last9=Eichler|first9=Florian|title=The Natural History of Adrenal Insufficiency in X-Linked Adrenoleukodystrophy: An International Collaboration|journal=The Journal of Clinical Endocrinology & Metabolism|volume=104|issue=1|year=2019|pages=118–126|issn=0021-972X|doi=10.1210/jc.2018-01307}}</ref> | ||
===Age=== | |||
*Childhood cerebral type commonly occurs in 3-10 years of age. | |||
*AMN type has a median age of 28 years. | |||
*Addison disease type occurs in 0 to �10 | |||
==References== | ==References== | ||
Revision as of 18:30, 23 June 2020
|
Adrenoleukodystrophy Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Adrenoleukodystrophy epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Adrenoleukodystrophy epidemiology and demographics |
|
Adrenoleukodystrophy epidemiology and demographics in the news |
|
Risk calculators and risk factors for Adrenoleukodystrophy epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Overview
Adrenoleukodystrophy is the most common peroxisomal disorder, with an estimated incidence of 1 in 17,000 births (male and female) and 1 in 21,000 males in the United States. The prevalence of X-linked adrenoleukodystrophy is approximately 1 in 20,000 individuals. This condition occurs with a similar frequency in all populations. The lifetime prevalence of adrenal insufficiency in ALD is ~80%.
Epidemiology and Demographics
Incidence
- Adrenoleukodystrophy is the most common peroxisomal disorder, with an estimated incidence of 1 in 17,000 births (male and female) and 1 in 21,000 males in the United States. [1]
Prevalence
- The prevalence of X-linked adrenoleukodystrophy is approximately 1 in 20,000 individuals. This condition occurs with a similar frequency in all populations.
- The lifetime prevalence of adrenal insufficiency in ALD is ~80%. [2]
Age
- Childhood cerebral type commonly occurs in 3-10 years of age.
- AMN type has a median age of 28 years.
- Addison disease type occurs in 0 to �10
References
- ↑ Wiens K, Berry SA, Choi H, Gaviglio A, Gupta A, Hietala A; et al. (2019). "A report on state-wide implementation of newborn screening for X-linked Adrenoleukodystrophy". Am J Med Genet A. 179 (7): 1205–1213. doi:10.1002/ajmg.a.61171. PMC 6619352 Check
|pmc=value (help). PMID 31074578. - ↑ Huffnagel, Irene C; Laheji, Fiza K; Aziz-Bose, Razina; Tritos, Nicholas A; Marino, Rose; Linthorst, Gabor E; Kemp, Stephan; Engelen, Marc; Eichler, Florian (2019). "The Natural History of Adrenal Insufficiency in X-Linked Adrenoleukodystrophy: An International Collaboration". The Journal of Clinical Endocrinology & Metabolism. 104 (1): 118–126. doi:10.1210/jc.2018-01307. ISSN 0021-972X.